

1 **SARS-CoV-2 detection using digital PCR for COVID-19 diagnosis,**
2 **treatment monitoring and criteria for discharge**

3 Renfei Lu¹, Jian Wang¹, Min Li¹, Yaqi Wang³, Jia Dong³ and Weihua Cai^{2*}

4

5 Affiliations

6 1. Nantong Third Hospital Affiliated to Nantong University, Clinical laboratory, Nantong,

7 Jiangsu,P.R. China

8 2. Nantong Third Hospital Affiliated to Nantong University, Infection Division. Nantong,

9 Jiangsu, P.R.China

10 3. RainSure Scientific Co, Ltd. Suzhou Industrial Park, Jiangsu, P.R, China

11 *Correspondence authors: Weihua Cai, Nantong Third Hospital Affiliated to Nantong Univer-

12 sity, Infection Division, Nantong, Jiangsu, P.R.China. Email: rainman78@163.com

13 **Summary**

14 **Background:** SARS-CoV-2 nucleic acid detection by RT-PCR is one of the criteria approved by
15 China FDA for diagnosis of COVID-19. However, inaccurate test results (for example, high false
16 negative rate and some false positive rate) were reported in both China and US CDC using RT-
17 PCR method. Inaccurate results are caused by inadequate detection sensitivity of RT-PCR, low
18 viral load in some patients, difficulty to collect samples from COVID-19 patients, insufficient
19 sample loading during RT-PCR tests, and RNA degradation during sample handling process.
20 False negative detection could subject patients to multiple tests before diagnosis can be made,
21 which burdens health care system. Delayed diagnosis could cause infected patients to miss the
22 best treatment time window. False negative detection could also lead to prematurely releasing
23 infected patients who still carry residual SARS-CoV-2 virus. In this case, these patients could
24 infect many others. A high sensitivity RNA detection method to resolve the existing issues of RT-
25 PCR is in need for more accurate COVID-19 diagnosis.

26 **Methods:** Digital PCR (dPCR) instrument DropX-2000 and assay kits were used to detect SARS-
27 CoV-2 from 108 clinical specimens from 36 patients including pharyngeal swab, stool and blood
28 from different days during hospitalization. Double-blinded experiment data of 108 clinical
29 specimens by dPCR methods were compared with results from officially approved RT-PCR
30 assay. A total of 109 samples including 108 clinical specimens and 1 negative control sample were
31 tested in this study. All of 109 samples, 26 were from 21 patients reported as positive by officially
32 approved clinical RT-PCR detection in local CDC and then hospitalized in Nantong Third
33 Hospital. Among the 109 samples, dPCR detected 30 positive samples on ORF1ab gene, 47
34 samples with N gene positive, and 30 samples with double positive on ORF1ab and N genes.

35 **Results:** The lower limit of detection of the optimize dPCR is at least 10-fold lower than that of
36 RT-PCR. The overall accuracy of dPCR for clinical detection is 96.3%. 4 out 4 of (100 %)
37 negative pharyngeal swab samples checked by RT-PCR were positive judged by dPCR based on
38 the follow-up investigation. 2 of 2 samples in the RT-PCR grey area (Ct value > 37) were

39 confirmed by dPCR with positive results. 1 patient being tested positive by RT-PCR was
40 confirmed to be negative by dPCR. The dPCR results show clear viral loading decrease in 12
41 patients as treatment proceed, which can be a useful tool for monitoring COVID-19 treatment.

42 **Conclusions:** Digital PCR shows improved lower limit of detection, sensitivity and accuracy,
43 enabling COVID-19 detection with less false negative and false positive results comparing with
44 RT-PCR, especially for the tests with low viral load specimens. We showed evidences that dPCR
45 is powerful in detecting asymptomatic patients and suspected patients. Digital PCR is capable of
46 checking the negative results caused by insufficient sample loading by quantifying internal
47 reference gene from human RNA in the PCR reactions. Multi-channel fluorescence dPCR system
48 (FAM/HEX/CY5/ROX) is able to detect more target genes in a single multiplex assay, providing
49 quantitative count of viral load in specimens, which is a powerful tool for monitoring COVID-19
50 treatment.

51 **Keywords:** SARS-CoV-2; Corvid-19; PCR assay; digital PCR; RT-PCR; false negative, false
52 positive, clinical detection, low viral load

53

54 **1. Introduction**

55 Coronavirus disease 2019 (COVID-19)¹ is now becoming a global public health problem, as the
56 definition of “the first pandemic in history that could be controlled” nominated by WHO². Severe acute
57 respiratory syndrome coronavirus 2 (SARS-CoV-2)³, the pathogen of COVID-19, was first isolated
58 and sequenced in early January 2020⁴. One-step reverse-transcription real-time PCR⁵ is recommended
59 by the Chinese Center for Disease Control and Prevention (CDC) as the “gold standard” for diagnosis
60 of COVID-19⁶. However, this commonly used method showed relatively lower sensitivity (about 30%-
61 50%) than expected. That could be partly due to low viral load in the pharyngeal of some patients, the
62 inappropriate transport and storage of samples, and relatively low detection limit of RT-PCR. Patients
63 with symptoms of COVID-19 but false negative detection of SARS-CoV-2 by RT-PCR may be treated

64 as if they were suffering regular flu or pneumonia, which results in high risk of viral transmission and
65 high mortality⁷. One of the requirements of discharging convalescent, “two consecutive days’ negative
66 detection for SARS-CoV-2 by RT-PCR”, may also lead to potential risk of viral transmission⁶.

67 Therefore, a more sensitive detection method is required for accurate SARS-CoV-2 diagnosis.

68 The concept of digital PCR was conceived and described in 1992⁸, and first published as “digital PCR”
69 in 1999⁹. The absolute quantification results come from Poisson statistics after limited dilution and
70 endpoint PCR^{10,11}. This method is also more robust against PCR inhibitors existing broadly in clinical
71 samples¹². The superior precision of digital PCR could be used for the detection of small fold change
72 of copy number variation or gene expression¹³. Digital PCR was also applied for rare mutation
73 detection in cancer diagnostics¹⁴, because the abundance of rare mutation in a partition is relatively
74 high and easier to detect¹⁵ than in bulk.

75 Here, we demonstrated the application of dPCR assay showing higher sensitivity by one order of
76 magnitude than RT-PCR. The dPCR assay can be used as a complementary method to the RT-PCR
77 detection method. Based on the results of this optimized dPCR system, we showed that the overall
78 accuracy of the dPCR for clinical SARS-CoV-2 detection is 96.3%.

79 **Ethics statement**

80 The Ethics Committee of the Nantong Third Hospital Affiliated to Nantong University approved
81 this study. Existing samples collected during standard diagnostic tests were tested and analyzed
82 retrospectively by dPCR. No extra burden was posed to patients.

83 **2. Materials and Methods**

84 **2.1. Clinical samples and RNA extraction**

85 The samples were obtained from clinical patients with fever, coughing, or lung inflammation
86 confirmed by CT images at Nantong Third Hospital Affiliated to Nantong University and local
87 CDC. Pharyngeal swabs were soaked in 1000 μ l PBS buffer. RNA from the pharyngeal swabs
88 was extracted using Liferiver Bio-Tech automatic nucleic acid extractor (Model: EX3600/2400)

89 following manufacturer's instruction.

90 **2.2. Primers and probes**

91 The primers and probes targeted the ORF1ab and N of SARS-CoV-2 according to Chinese CDC.

92 Target 1 (ORF1ab), forward: 5'-CCCTGTGGGTTTTACTTAA-3', reverse: 5'-

93 ACGATTGTGCATCAGCTGA-3', probe: 5'-FAM-

94 CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3'; Target 2 (N), forward: 5'-

95 GGGGAACTTCTCCTGCTAGAAT-3', reverse: 5'-CAGACATTTTGCTCTCAAGCTG-3', probe:

96 5'-HEX-TTGCTGCTGCTTGACAGATT-TAMRA-3'. Internal references gene (RPP30), forward:

97 5'-AGT GCA TGC TTA TCT CTG ACA G-3', reverse: 5'-GCA GGG CTA TAG ACA AGT

98 TCA-3', probe: 5'-Cy5-TTT CCT GTG AAG GCG ATT GAC CGA-BHQ-3'.

99 **2.3. Workflow**

100 For dPCR workflow, all the procedures follow the manufacturer's instructions of RainSure

101 DropX-2000 Droplet Digital PCR System using RainSure Novel Coronavirus (SARS-CoV-2)

102 Nucleic Acid Detection Kit. Briefly, 25 μ l of reaction mix is required for each reaction on the

103 DropX-2000 platform. Each 25 μ l is comprised of 10 μ l of SARS-CoV-2 one-step RT digital PCR

104 master mix, 1 μ l of enzyme mix, 14 μ l RNA extracted from patient samples. Following the

105 instrument touch screen's prompt, microfluidic droplet generation and detection cartridges were

106 placed on a cartridge loading stage. 70 μ l of droplet generation oil and 25 μ l of reaction mix were

107 loaded into an oil well and a sample well, respectively. After the reagent loading process, a gasket

108 with filters was mounted onto the wells of the reagent loaded cartridge. The instrument retrieved

109 the cartridge loading stage and started droplet generation process automatically followed by a

110 thermal cycling protocol: step 1, 49°C for 20 min (reverse transcription); step 2, 97 °C for 12 min

111 (DNA polymerase activation); step 3, 40 cycles of 95.3°C for 20 sec (denaturation) and 52°C for 1

112 min (annealing); step 4, 20°C (cooling) for infinite hold. The cartridges were then transferred and

113 loaded onto the DScanner-2000 for multi-channel fluorescence detection of droplets. A single

114 multiplex assay measures the concentration of 3 different target genes, ORF1ab, N gene and

115 RPP30 respectively.

116 For RT-PCR workflow, the primers and probes are from Liferiver Bio-Tech. A25- μ l reaction was
117 set up containing 5 μ l of RNA, 19 μ l of reaction buffer provided with the one step RT-PCR
118 system and 1 μ l enzyme mix. Thermal cycling was performed at 45°C for 10 min for reverse
119 transcription followed by 95°C for 3 min and then 45 cycles of 95 °C for 15 sec, 58 °C for 30 sec
120 in SLAN 96P real time PCR system.

121 **2.4. Data analysis**

122 Analysis of the dPCR data was performed with analysis software GeneCount V1.60b0318
123 (RainSure Scientific). Concentrations of the target RNA sequences, along with their Poisson-
124 based 95% confidence intervals were also provided by the software. Fluorescence channels of
125 FAM, HEX and Cy5 were scanned to detect ORF1ab gene, N gene and RPP30 gene respectively.
126 The positive populations for each target gene were identified using positive and negative controls
127 with single primer–probe sets for each fluorescence channel. The concentration reported by
128 GeneCount has the unit of copies of template per microliter of the final 1 \times dPCR reaction, which
129 was also reported and used in all the subsequent analysis.

130 **3. Results**

131 **3.1. Comparison of the lower limit of detection between dPCR and the standard RT-PCR**

132 Lower limit of detection (LLoD) of RT-PCR and dPCR was compared using serial dilution of clinical
133 specimen. The starting clinical specimen showed Ct value of 35 in RT-PCR. The specimen was diluted
134 using virus storage solution. Each dilution was 5 fold. A total of 7 dilutions (8 samples S1-S8
135 including the starting stock) were tested by both RT-PCR and dPCR assays. As shown in **Figure 1** and
136 **Table 2** RT-PCR failed to detect S3, while dPCR was able to detect S3 and S4. dPCR showed
137 negative results for S5 through S8. dPCR assay showed at least 10 times lower LLoD than RT-PCR
138 assay. However, LLoQ (lower limit of quantification) was estimated to be larger than the viral
139 concentration in S3.

140 **3.2. Comparison of dPCR assay with RT-PCR assay using clinical samples**

141 A total of 108 samples were taken from 38 individuals (**Table 1**) at various time points during the
142 course of their treatment and quarantine. When assessed with RT-PCR method, the result showed
143 reasonable consistency between different targets (**Table 3**).

144 Results from dPCR targeting ORF1ab gene were also consistent with that from RT-PCR result (**Table**
145 **4**). In particular, 4 positive samples from 3 patients based on dPCR assay were not detected by RT-
146 PCR. The computerized tomography (CT) results of the 3 patients showed 1 patient's lung texture
147 thickening, no pneumonia imaging characteristics; 1 patient had two lungs infections,; and 1 patient
148 showed inflammation of the right lung and lower lobe. But RT-PCR assay failed to detect these 4
149 samples, and generated negative results.

150 Digital PCR targeting N gene exhibited higher sensitivity than that targeting ORF1ab gene. As shown
151 in **Table 5**, among 47 positive samples as determined by N gene, only 30 were positive as determined
152 by ORF1ab gene. For the remaining 17 samples, 15 of them were from patients clinically determined
153 to be positive based on other factors. One was a suspected case. One of them were of unknown clinical
154 classification. In particular, one was actually discharged based on RT-PCR assay result, although a
155 retrospective dPCR test detected the virus. In contrast, as long as a sample is deemed positive by
156 ORF1ab gene, all but one were positive by N gene.

157 **3.3. dPCR assay result during the course of treatment**

158 Digital PCR also provides a window to monitor the progression and treatment of disease more
159 consistently than RT-PCR. We analyzed positive samples from 3 patients based on dPCR assay that
160 were not consistently detected by RT-PCR.

161 Patient 33 was first identified as SAR-CoV-2 positive by RT-PCR from pharyngeal swab with
162 ORF1ab gene Ct of 32.3 and N gene Ct of 33.2 (**Table 6**). dPCR showed ORF1ab concentration of
163 28.3 copies/ μ l, N gene concentration of 35.2 copies/ μ l and internal reference gene concentration of
164 32.8 copies/ μ l on January 27, 2020 (**Figure 2** and **Table 6**). The patient was treated in hospital under

165 quarantine. The RT-PCR results from the same patient's pharyngeal swab specimen were
166 undetermined for both ORF1ab and N gene on February 5, 2020, after being treated for 9 days. dPCR
167 results showed ORF1ab gene concentration of 0.44 copies/ μ l, N gene concentration of 0.62 copies/ μ l
168 and internal reference gene of 130.97 copies/ μ l. The ratio between ORF1ab gene and internal
169 references gene decreased from 0.86 to 0.003 and the ratio between N gene and internal references
170 gene decreased from 1.07 to 0.005 from January 27 to February 5. The dPCR results showed
171 significant but incomplete viral clearance. Chest computed tomography (CT) results of the patient on
172 January 27 and February 5 were both normal, showing no infection. The patient showed no fever,
173 coughing, cold, muscle pain, pharynx, chest pain, diarrhea or nausea. dPCR was able to detect residual
174 SARS-CoV-2 virus load from this asymptomatic patient.

175 RT-PCR and dPCR results from Patient 8 on Jan. 23, 2020 both showed high SARS-CoV-2 viral load
176 from the pharyngeal swab (**Table 7** and **Figure 3**). The patient's specimens were subsequently tested
177 by RT-PCR and dPCR on February 5th and February 21. After 13 days of treatment (Feb. 5th), RT-
178 PCR couldn't detect any virus from pharyngeal swab. However, follow-up tests performed after
179 another 16 days (Feb. 21st), RT-PCR results turned out to be positive from pharyngeal swab, but
180 negative on stool specimen. CT results of this patient showed lung texture thickening without features
181 characteristic of pneumonia. The patient also showed symptoms of fever, coughing, muscle pain and
182 headache. The inconsistent results would confuse clinicians for diagnosis and treatment plan. dPCR
183 assay, however, consistently reported positive results over the whole course of 29 days for specimens
184 from pharyngeal swab. The ratio of ORF1ab gene and internal reference gene from pharyngeal swab
185 by dPCR from patient 8 decreased from 1.66 to 0.001 from Jan. 23rd to Feb. 21st. The ratio of N gene
186 and internal reference gene from pharyngeal swab by dPCR from patient 8 decreased from 2.41 to
187 0.0007 from Jan. 23rd to Feb. 21st. RT-PCR failed to detect the trace amount of SARS-CoV-2 virus
188 from stool on Feb. 21st (ORF1ab gene Ct > 41, N gene Ct undetermined). dPCR results were positive
189 for patient 8's stool specimen with ORF1ab gene concentration of 0.72 copies/ μ l and N gene
190 concentration of 0.93 copies/ μ l.

191 Patient 9 first showed symptoms of fever, coughing and muscle pains on Feb. 4th, 2020 and then
192 hospitalized on Feb. 13th, 2020. However, pharyngeal swabs were negative by RT-PCR from Feb.
193 14th to Feb. 25th for all 6 RT-PCR tests performed. CT results showed infection of both lungs.
194 However, due to the negative RT-PCR results, the patient was categorized as a suspected case despite
195 her positive CT results and symptoms. Although dPCR showed negative result on Feb. 14th, the day
196 after the patient intake, low SARS-CoV-2 viral load (ORF1ab gene concentration of 0.34 copies/ μ l and
197 N gene of 0.43 copies/ μ l) was reported for the sample from Feb. 18th. The negative results of February
198 14th were most likely due to insufficient sample loading. The concentration of internal reference gene
199 was only 1.892 copies/ μ l, indicating low RNA load in the test. One Feb. 18th, dPCR test result was
200 positive with the internal reference gene concentration at 20.8 copies/ μ l. It also suggested that the Feb.
201 14th dPCR results were negative due to insufficient RNA loading which may be related to improper
202 sample collection or RNA loss during sample nucleic acid extraction. CT scan result supported the
203 conclusion from dPCR that this patient was infected with SARS-CoV-2. This patient was treated with
204 Moxifloxacin, Arbidol and Pudilan.

205 These examples support our conclusion that dPCR offers improved sensitivity and consistency when
206 testing specimens from patients during the course of treatment. dPCR is also able to detect low viral
207 load in asymptomatic infection patients and suspected patients. dPCR can check if the negative result
208 was caused by insufficient RNA loading by quantify the copy number of internal reference gene
209 RPP30.

210 **3.4. dPCR assay results from different sample locations**

211 For 8 patients, both pharyngeal and stool samples were collected on the same day and tested. RT-PCR
212 assay targeting ORF1ab gene reported positive result for all pharyngeal samples, but only 3 positive
213 results for stool samples. dPCR assay targeting ORF1ab gene reported 7 positive results for
214 pharyngeal samples, but only 1 positive result for stool samples. dPCR assay targeting N gene
215 reported 8 positive results for pharyngeal samples, and 7 positive results for stool samples. Among
216 these 8 patients, serum samples from 6 of them were also tested. The results were all negative when

217 using RT-PCR and dPCR targeting ORF1ab genes, but dPCR targeting N gene reported 2 positive
218 results. From dPCR results, it clearly indicates viral load in patients is throat > stool > blood.

219 The samples with ORF1ab positive detected in throat for dPCR is 6 more than RT-PCR (27 vs 21).

220 The samples with ORF 1ab positive detected in blood and sputum for dPCR is 1 more than RT-PCR (1
221 vs 0). While the samples with ORF1ab positive detected in stool for dPCR is 2 less than RT-PCR (2 vs
222 4). Therefore, dPCR showed less sensitivity than RT-PCR in specimens from stool, higher sensitivity
223 than RT-PCR in specimens from throat, blood and sputum. Different detection sensitivity of dPCR
224 assay for different sample types may require further experiments to draw a conclusion.

225 **3.5. dPCR assay results for internal reference gene**

226 Stool specimen from patient 4 on Feb. 24th was tested as negative by both RT-PCR and dPCR.

227 However, the internal reference gene result by dPCR is 0 suggesting no RNA was loaded in either tests
228 or the PCR reactions were inhibited. The samples need to be re-collected to re-run the tests. The
229 internal reference gene of dPCR assay serves as a quality control to ensures no PCR inhibition
230 happened and RNA extraction was successful. Without such a control in RT-PCR assay, the patient
231 could have been discharged prematurely, putting those in close contact at risk of being infected.

232

233 **4. Discussion**

234 We first demonstrated that the LOD of dPCR assay is at least 10 times better than that of RT-PCR
235 assay using serial dilution of the same clinical sample. Higher sensitivity, along with more reliable
236 quantification of viral load, provides valuable information to help clinicians choose the appropriate
237 treatment plan¹⁶. To demonstrate its application in clinical settings, we performed head-to-head
238 comparison of RT-PCR and dPCR assays using a cohort of 39 patients totaling 109 samples obtained
239 at different stage of the treatment and from different locations..

240 We observed that the result of dPCR targeting ORF1ab gene is consistent with RT-PCR targeting the
241 same. In particular, dPCR assay detected 4 positive samples that were determined to be negative by
242 RT-PCR assay. Although there were also 3 positive samples from RT-PCR assay that were deemed

243 negative by dPCR-ORF1ab assay (the Ct values of ORF1ab for those 3 positive samples were > 38,
244 which are in the grey area of RT-PCR), they were all positive from dPCR assay targeting N gene.
245 Combing the CT results and test history of the 3 positive samples, 1 of the positive samples are false
246 positive by RT-PCR (Patient 7). Combining the result of both dPCR assays provides a more sensitivity
247 and accurate method to detect SARS-COV-2.

248 The dPCR results also showed higher sensitivity when the primer and probe are designed against N
249 gene. It may be explained by the higher copy number of RNA for N gene arising from the replication
250 process of the virus^{17,18}. Interestingly, RT-PCR assay didn't exhibit significance difference between the
251 two targets. Further study is warranted to elucidate the underlying mechanism. It is well recognized
252 that dPCR assays are less susceptible to the existence of PCR inhibitors, and the results are thus more
253 reliable in general^{11,19}.

254 With dPCR assay, we were able to track the progress of the treatment by monitoring the viral load
255 from samples obtained on different dates. RT-PCR suffered from sporadic appearance of positive
256 result which puzzled clinicians. dPCR results, in contrast, faithfully reflected the onset and healing of
257 the disease, when examined together with relevant radiological evidence and treatment history. dPCR
258 showed evidences of higher sensitivity to detect low virus load in patients who showed mild symptoms
259 or have been treated for COVID-19 than RT-PCR.

260 We were also able to compare the viral load in different organs thanks to higher sensitivity of dPCR
261 assay. The dPCR assay provides quantitative information on the viral load of specimens collected from
262 different locations of the same patient. In all but one cases, the viral load is the highest in pharyngeal
263 samples, lower in stool samples and the lowest in serum. Interestingly, a considerable amount of virus
264 was found in the phlegm of one of the patients whose pharyngeal sample was negative. These
265 observations may provide valuable insight into the pathology of this emerging disease²⁰.

266 **5. Conclusions**

267 Digital PCR shows improved lower limit of detection, sensitivity and accuracy, enabling COVID-19

268 detection with less false negative and false positive results comparing with RT-PCR, especially
269 for the tests with low viral load specimens. We showed evidences that dPCR is powerful in
270 detecting asymptomatic patients and suspected patients. Digital PCR is capable of flagging the
271 negative results caused by insufficient sample loading by quantifying internal reference gene from
272 human RNA in the PCR reactions. Multi-channel fluorescence dPCR system
273 (FAM/HEX/CY5/ROX) is able to detect more target genes in a single multiplex assay, providing
274 quantitative count of viral load in specimens, which is a powerful tool for monitoring COVID-19
275 treatment.

276 **Author Contributions**

278 Weihua Cai conceptualized the study design; Renfei Lu, Jian Wang recruited the patients, collected
279 specimens, did the laboratory tests and interpreted the results; Jia Dong did the part of the laboratory
280 tests. Yaqi Wang analyzed the data; Renfei Lu wrote the drafts of the manuscript; all authors read
281 and approved the final report and draft.

282 **Funding**

283 This study was supported by Natural Science Research Project of Nantong Science and
284 Technology Bureau (grant nos. MS12019048) and Special fund for Chinese Traditional Medicine
285 hospital of Jiangsu Providence (JSZYJ202001-6).

286 **Acknowledgement**

287 We are grateful to RainSure Scientific for their great support to this work. We are grateful to Drs.
288 Yu Liu, Drs. Yunfeng Ling, Drs. Chen Li, Drs. Xuan Zhang and Mr. Haifeng Wang, Mr. Yajun
289 Xu and Mr. Hua Zhang for their support in experiment design, data analysise and instrumentation.

290 **References**

- 292 1. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in
293 China. *Nature*. February 2020. doi:10.1038/s41586-020-2008-3
- 294 2. WHO. WHO Director-General's opening remarks at the media briefing on COVID-19 - 9
295 March 2020. [https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---9-march-2020)
296 [media-briefing-on-covid-19---9-march-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---9-march-2020). Published 2020. Accessed March 15, 2020.
- 297 3. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and
298 pathogenesis. *J Med Virol*. 2020;92(4):418-423. doi:10.1002/jmv.25681

- 299 4. Chen L, Liu W, Zhang Q, et al. RNA based mNGS approach identifies a novel human
300 coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. *Emerg Microbes Infect.*
301 2020;9(1):313-319. doi:10.1080/22221751.2020.1725399
- 302 5. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases.
303 [https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-](https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117)
304 [human-cases-20200117](https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117). Accessed March 15, 2020.
- 305 6. China public health commission. Clinical guidance for the diagnosis and treatment of COVID-
306 19 (7th edition).
- 307 7. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
308 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 □ 314 Cases From the
309 Chinese Center for Disease Control and Prevention. *JAMA*. February 2020.
310 doi:10.1001/jama.2020.2648
- 311 8. Pohl G, Shih LM. Principle and applications of digital PCR. In: *Expert Review of Molecular*
312 *Diagnostics*. Vol 4. ; 2004:41-47. doi:10.1586/14737159.4.1.41
- 313 9. Vogelstein B, Kinzler KW. Digital PCR. *Proc Natl Acad Sci U S A*. 1999;96(16):9236-9241.
314 doi:10.1073/pnas.96.16.9236
- 315 10. Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital PCR system for
316 absolute quantitation of DNA copy number. *Anal Chem*. 2011;83(22):8604-8610.
317 doi:10.1021/ac202028g
- 318 11. Hindson CM, Chevillet JR, Briggs HA, et al. Absolute quantification by droplet digital PCR
319 versus analog real-time PCR. *Nat Methods*. 2013;10(10):1003-1005. doi:10.1038/nmeth.2633
- 320 12. Caviglia GP, Abate ML, Tandoi F, et al. Quantitation of HBV cccDNA in anti-HBc-positive
321 liver donors by droplet digital PCR: A new tool to detect occult infection. *J Hepatol*. 2018;69(2):301-
322 307. doi:10.1016/j.jhep.2018.03.021
- 323 13. Miyaoka Y, Mayerl SJ, Chan AH, Conklin BR. Detection and quantification of HDR and
324 NHEJ induced by genome editing at endogenous gene loci using droplet digital PCR. In: *Methods in*
325 *Molecular Biology*. Vol 1768. Humana Press Inc.; 2018:349-362. doi:10.1007/978-1-4939-7778-9_20
- 326 14. Postel M, Roosen A, Laurent-Puig P, Taly V, Wang-Renault SF. Droplet-based digital PCR
327 and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic
328 perspective. *Expert Rev Mol Diagn*. 2018;18(1):7-17. doi:10.1080/14737159.2018.1400384
- 329 15. Brunetto GS, Massoud R, Leibovitch EC, et al. Digital droplet PCR (dPCR) for the precise
330 quantification of human T-lymphotropic virus 1 proviral loads in peripheral blood and cerebrospinal
331 fluid of HAM/TSP patients and identification of viral mutations. *J Neurovirol*. 2014;20(4):341-351.
332 doi:10.1007/s13365-014-0249-3
- 333 16. Working Group of 2019 Novel Coronavirus, Peking Union Medical College Hospital.
334 [Diagnosis and clinical management of 2019 novel coronavirus infection: an operational
335 recommendation of Peking Union Medical College Hospital (V2.0)]. *Zhonghua nei ke za zhi*.
336 2020;59(3):186-188. doi:10.3760/cma.j.issn.0578-1426.2020.03.003
- 337 17. Hussain S, Pan J, Chen Y, et al. Identification of Novel Subgenomic RNAs and Noncanonical

- 338 Transcription Initiation Signals of Severe Acute Respiratory Syndrome Coronavirus. *J Virol.*
339 2005;79(9):5288-5295. doi:10.1128/jvi.79.9.5288-5295.2005
- 340 18. Thiel V, Ivanov KA, Putics Á, et al. Mechanisms and enzymes involved in SARS coronavirus
341 genome expression. *J Gen Virol.* 2003;84(9):2305-2315. doi:10.1099/vir.0.19424-0
- 342 19. White RA, Blainey PC, Fan HC, Quake SR. Digital PCR provides sensitive and absolute
343 calibration for high throughput sequencing. *BMC Genomics.* 2009;10:116. doi:10.1186/1471-2164-10-
344 116
- 345 20. Xu Z, Shi L, Wang Y, et al. Case Report Pathological findings of COVID-19 associated with
346 acute respiratory distress syndrome. *Lancet Respir.* 2020;2600(20):19-21. doi:10.1016/S2213-
347 2600(20)30076-X
- 348

349 **Figure legends**

350 **Table 1.** Data of RT-PCR, dPCR and CT results from 109 clinical specimens collected from 38
351 patients, including pharyngeal swab, stool and serum.

352



Table1_Worksheet
in SARS-CoV-2 det

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374



375

376



377

378 **Figure 1.** Graphs and data of lower limit of detection (LLoD) of RT-PCR and dPCR using series
379 dilution of clinical specimen.



380 The clinical specimen showed RT-PCR Ct value at 35. The specimen was diluted using virus
381 storing solution 5 for each dilution. Each dilution is 5 fold. Total of 7 dilutions (8 concentrations)
382 were tested by both RT-PCR and dPCR assays. Orange color is internal reference, green is N gene,
383 blue is ORF1ab for both RT-PCR and dPCR. S1 is original specimen (left RT-PCR, right dPCR).
384 S2 is S1 specimen 5X dilution (left RT-PCR, right dPCR). S3 is S2 specimen 5X dilution (left
385 RT-PCR, right dPCR). S4 is S3 5X dilution (left RT-PCR, right dPCR). S5-S8 are 5X series
386 dilutions from S4 specimen. The dPCR assay showed at least 10 fold lower LLoD than RT-PCR
387 assay. RT-PCR failed to detect at S3 dilution, dPCR was able to detect S3 and S4 dilution.
388 However. LLoQ (lower limit of quantification) is above S3 concentration.





S1



S2



S3



S4

390 **Table 2.** RT-PCR and dPCR results of S1-S8 specimens

	RT-PCR (Ct)		dPCR result (copies/ μ l)	
	ORF1ab gene	N gene	ORF1ab gene	N gene
S1	35	33	5.24	9.54
S2	38	35	0.88	1.57
S3	undetermined	38	0.10	0.10
S4	undetermined	undetermined	0.10	0.10
S5	undetermined	undetermined	0	0
S6	undetermined	undetermined	0	0
S7	undetermined	undetermined	0	0
S8	undetermined	undetermined	0	0

391

392 **Table 3.** Consistency between RT-PCR assays targeting ORF1ab gene and N gene.

RT-PCR ORF1ab Gene (result)	RT-PCR N Gene (result)		Total
	negative	positive	
negative	80	0	80
positive	2	25	27
Total	82	25	107

393

394 **Table 4.** Consistency between dPCR assay targeting ORF1ab gene and RT-PCR assay targeting the
395 same.

RT-PCR ORF1ab	dPCR ORF1ab (result)		Total
	Negative	Positive	

Gene (result)			
negative	76	4	80
positive	3	25	28
Total	79	29	108

396


397 **Table 5.** Sensitivity of dPCR assays targeting ORF1ab gene and N gene.

dPCR ORF1ab gene (result)	dPCR N gene (result)		Total
	Negative	Positive	
Negative	62	17	79
Positive	0	30	30
Total	62	47	109

398

399 **Figure 2.** dPCR results of SAR-CoV-2 tests from patient 33.

400 2A is test result from Patient 33 on Jan. 27th, 2020. 2B is test results from patient 33 on Feb 5th,
401 2020. Left is FAM(ORF1ab) Y axis, HEX (N) X axis; middle is FAM (ORF1ab) Y axis, Cy5
402 (internal reference) X axis; right is the concentration call of ORF1ab, N and internal reference
403 genes.




404 **Table 6.** RT-PCR and dPCR results of Patient 33 on Jan. 27th, 2020 and Feb. 5th, 2020.

	RT-PCR (Ct)		dPCR result (copies/μl) 25 μl reaction volume	
	ORF1ab gene	N gene	ORF1ab gene	N gene
Jan. 27 th , 2020	32.3185	33.2087	28.342	35.199
Feb. 5 th , 2020	negative	negative	0.442	0.619

405 **Figure 3.** dPCR results of SAR-CoV-2 tests from patients 2.

406 3A is test result from Patient 8 on Jan. 23rd, 2020. 3B is test results from patient 8 on Feb. 5th,
 407 2020. 3C is test results from patient 8 on Feb. 21st, 2020. Left is FAM (ORF1ab) Y axis, HEX (N)
 408 X axis; middle is FAM (ORF1ab) Y axis, Cy5 (internal reference) X axis; right is the
 409 concentration call of ORF1ab, N and internal reference genes.



410 **Table 7.** RT-PCR and dPCR results of patient 8 on Jan. 23rd, 2020, Feb. 5th, 2020 and Feb. 21st, 2020.

	RT-PCR (Ct)		dPCR (copies/ μ l)25 μ l reaction volume		Ratio of genes from dPCR assay results	
	ORF1ab gene	N gene	ORF1ab gene	N gene	ORF1ab/Reference	N/Reference
Jan. 23rd, 2020	22.0	33.0	301.0	436.4	1.66	2.41
Feb. 5th, 2020	negative	negative	0.18	0.26	0.0025	0.0022
Feb. 21st, 2020	34.6	39.0	0.29	0.19	0.0012	0.0008